Zobrazeno 1 - 10
of 27
pro vyhledávání: '"John Aspegren"'
Publikováno v:
Frontiers in Veterinary Science, Vol 7 (2020)
The aim of this randomized, double-blind, placebo-controlled, parallel group clinical field study was to evaluate the effect of detomidine oromucosal gel in alleviating anxiety and fear in horses. Sixteen horses with a history of acute anxiety and fe
Externí odkaz:
https://doaj.org/article/dfed03ca3def4a00ad929b0ce994fb88
Autor:
Robert Hugh Jones, Karim Fizazi, Nicholas D. James, Teuvo L. Tammela, Nobuaki Matsubara, Frank Priou, Phillipe Beuzeboc, Thierry Lesimple, Petri Bono, Vesa Kataja, Jorge A. Garcia, Andrew Protheroe, John Aspegren, Heikki Joensuu, Iris Kuss, Silke Thiele, Sabine Fiala-Buskies, Eglis Vjaters
Publikováno v:
Journal of Urology. 207
Autor:
Mayank Singhal, Elina Turunen, Tuula Ahtola-Sätilä, John Aspegren, J. Raymond Bratty, Rainard Fuhr, Krista Ojala, Bert van Veen, Leena Peltonen
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 177
Particle size reduction leads to an increase in the drug dissolution rate, which in turn can lead to a substantial increase in the bioavailability of a poorly soluble compound. To improve bioavailability, a practically insoluble investigational drug,
Autor:
Jyrki, Lehtimäki, Niina, Jalava, Kaisa, Unkila, John, Aspegren, Antti, Haapalinna, Ullamari, Pesonen
Publikováno v:
European journal of pharmacology. 923
The pharmacological profile of tasipimidine, a novel orally active α
Publikováno v:
The Veterinary recordREFERENCES. 189(12)
INTRODUCTION Many dogs are anxious and/or fearful in veterinary clinics and exhibit avoidant and/or defensive behaviour. The purpose of pharmacological interventions is to reduce anxiety and to enable patient-friendly, low stress physical examination
Autor:
Robin Wyn, Vicki Black, Katherine Hughes, David Bartram, Samuel Beck, Emily Blackwell, L. J. Davison, Toby D. Collen, Jess Williams, Edward J Hall, John Aspegren, Christopher Hoey, Melanie Dobromylskyj, Terttu Lamminen, Camilla Pegram, S Brown, Nicholas Bexfield, Melanie J Hezzell, David Brodbelt, Rory Scrace, Valeria Bergomi, Andrea Wright, Vicki Baldrey Kate Kim, Edwina Gildea, John W. Wills, Kristina DiPietrantonio, Anna Garvey, David B. Church, Tim J. Williams, Dan G. O’Neill, Ashley Enstone, Nirav Nagda, Aarti Kathrani, Louise Longstaff, Nicholas Hope, R.F. Geddes, Danielle Riley, Kristina Hunter
Publikováno v:
BSAVA Congress 2021: Clinical abstract presentations ISBN: 9781913859039
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fbfe56c54c30c5dd4e7ecb6f5c0235b
https://doi.org/10.22233/9781913859039.9
https://doi.org/10.22233/9781913859039.9
Autor:
Egils Vjaters, Karim Fizazi, Nicholas D. James, Teuvo Tammela, Nobuaki Matsubara, Frank Priou, Thierry Lesimple, Petri Bono, Vesa V Kataja, Jorge A. Garcia, Andrew Protheroe, John Aspegren, Heikki Joensuu, Iris Kuss, Silke Thiele, Sabine Fiala-Buskies, Robert Hugh Jones
Publikováno v:
Journal of Clinical Oncology. 40:90-90
90 Background: Darolutamide, a structurally distinct and highly potent androgen receptor inhibitor, had a consistently favorable safety and tolerability profile in patients with nonmetastatic castration-resistant prostate cancer in ARAMIS, and discon
Autor:
Johann S. de Bono, Petri Bono, John Aspegren, Sophie Postel-Vinay, Amir Snapir, Malaka Ameratunga, Irene Brana, Ruth Plummer, Timo Korjamo
Publikováno v:
British Journal of Cancer
Scientia
Scientia
BackgroundBromodomain and extra-terminal domain (BET) proteins are reported to be epigenetic anti-cancer drug targets. This first-in-human study evaluated the safety, pharmacokinetics and preliminary anti-tumour activity of the BET inhibitor ODM-207
Autor:
Lars Edenbrandt, R. Jones, Karim Fizazi, Mika Mustonen, Christophe Massard, Elin Trägårdh, Leena Mattila, Per Wollmer, Eva Bondesson, Mariana Reza, Anders Bjartell, John Aspegren
Publikováno v:
European Urology Focus. 2:547-552
Background\ud \ud ODM-201, a new-generation androgen receptor inhibitor, has shown clinical efficacy in prostate cancer (PCa). Quantitative methods are needed to accurately assess changes in bone as a measurement of treatment response. The Bone Scan
Autor:
Mika Mustonen, Teuvo L.J. Tammela, Christophe Massard, Petri Bono, John Aspegren, Karim Fizazi, Neal D. Shore
Background: ODM-201, a new androgen receptor antagonist for treatment of metastatic castration-resistant prostate cancer (mCRPC), demonstrated antitumour activity and acceptable tolerability in phase 1/2 trials. Objective: To determine the antitumour
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a6913e4ccf93c8518a0ad7f2f4947c1
http://hdl.handle.net/10138/299672
http://hdl.handle.net/10138/299672